Literature DB >> 12643277

A new perspective on V3 phenotype prediction.

Satish Pillai1, Benjamin Good, Douglas Richman, Jacques Corbeil.   

Abstract

The particular coreceptor used by a strain of HIV-1 to enter a host cell is highly indicative of its pathology. HIV-1 coreceptor usage is primarily determined by the amino add sequences of the V3 loop region of the viral envelope glycoprotein. The canonical approach to sequence-based prediction of coreceptor usage was derived via statistical analysis of a less reliable and significantly smaller data set than is presently available. We aimed to produce a superior phenotypic classifier by applying modern machine learning (ML) techniques to the current database of V3 loop sequences with known phenotype. The trained classifiers along with the sequence data are available for public use at the supplementary website: http://genomiac2.ucsd.edu:8080/wetcat/v3.html and http://www.cs.waikato.ac.nz/ml/weka[corrected].

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12643277     DOI: 10.1089/088922203762688658

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  49 in total

Review 1.  HIV-1 tropism.

Authors:  Aikichi Iwamoto; Noriaki Hosoya; Ai Kawana-Tachikawa
Journal:  Protein Cell       Date:  2010-07-07       Impact factor: 14.870

2.  Co-receptor tropism prediction among 1045 Indian HIV-1 subtype C sequences: Therapeutic implications for India.

Authors:  Ujjwal Neogi; Sreenivasa B Prarthana; George D'Souza; Ayesha Decosta; Vijesh S Kuttiatt; Udaykumar Ranga; Anita Shet
Journal:  AIDS Res Ther       Date:  2010-07-21       Impact factor: 2.250

3.  A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences.

Authors:  Mark A Jensen; Mia Coetzer; Angélique B van 't Wout; Lynn Morris; James I Mullins
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

5.  Viral tropism and antiretroviral drug resistance in HIV-1 subtype C-infected patients failing highly active antiretroviral therapy in Johannesburg, South Africa.

Authors:  Irene Ketseoglou; Azwidowi Lukhwareni; Kim Steegen; Sergio Carmona; Wendy S Stevens; Maria A Papathanasopoulos
Journal:  AIDS Res Hum Retroviruses       Date:  2013-12-13       Impact factor: 2.205

Review 6.  Bioinformatic analysis of HIV-1 entry and pathogenesis.

Authors:  Benjamas Aiamkitsumrit; Will Dampier; Gregory Antell; Nina Rivera; Julio Martin-Garcia; Vanessa Pirrone; Michael R Nonnemacher; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

7.  Prediction of co-receptor usage of HIV-1 from genotype.

Authors:  J Nikolaj Dybowski; Dominik Heider; Daniel Hoffmann
Journal:  PLoS Comput Biol       Date:  2010-04-15       Impact factor: 4.475

8.  Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping.

Authors:  Mattia C F Prosperi; Laura Bracciale; Massimiliano Fabbiani; Simona Di Giambenedetto; Francesca Razzolini; Genny Meini; Manuela Colafigli; Angela Marzocchetti; Roberto Cauda; Maurizio Zazzi; Andrea De Luca
Journal:  Retrovirology       Date:  2010-06-30       Impact factor: 4.602

9.  Accurate and efficient gp120 V3 loop structure based models for the determination of HIV-1 co-receptor usage.

Authors:  Majid Masso; Iosif I Vaisman
Journal:  BMC Bioinformatics       Date:  2010-10-05       Impact factor: 3.169

10.  V3 loop sequence space analysis suggests different evolutionary patterns of CCR5- and CXCR4-tropic HIV.

Authors:  Katarzyna Bozek; Alexander Thielen; Saleta Sierra; Rolf Kaiser; Thomas Lengauer
Journal:  PLoS One       Date:  2009-10-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.